Navigation Links
Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poor's Market Access Program
Date:7/3/2008

XI'AN, China, July 3 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production in China, announced today that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of Standard & Poor's Advisor Insight. The company information to be made available through this program includes share price, volume, dividends, shares outstanding, company financial position, and earnings. Standard & Poor's Advisor Insight is an Internet-based research engine used by more than 100,000 investment advisors. A public version of the site is available at http://www.advisorinsight.com .

In addition, information about companies in Standard & Poor's Market Access Program will be available via S&P's Stock Guide database, which is distributed electronically to virtually all major quote vendors. As part of the program, a full description of Huifeng Bio-Pharmaceutical Technology, Inc. will also be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 states under their Blue Sky Laws.

About Huifeng Bio-Pharmaceutical Technology, Inc.

Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. Additional information about Huifeng can be found from their website, http://www.hfgb.cn .

Company information distributed through the Market Access Program is based upon information that Standard & Poor's considers to be reliable, but neither Standard & Poor's nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.

For more information, please contact:

Huifeng Bio-Pharmaceutical Technology, Inc.

Daniel Carlson

Primary Capital LLC.

Tel: +1-415-460-1165

Email: DCarlson@PrimaryLLC.com

Standard & Poor's Customer Contact:

Richard Albanese

Tel: +1-212-438-3647

Email: richard_albanese@sandp.com

Standard and Poor's Media Relations Contact:

Michael Privitera

Tel: +1-212-438-6679

Email: michael_privitera@sandp.com


'/>"/>
SOURCE Huifeng Bio-Pharmaceutical Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
2. Huifeng Bio-Pharmaceutical (HFGB) to Release First Quarter 2008 Earnings Results on May 15, 2008
3. Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities
4. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
7. Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou
8. Sentry Enhances Offerings with Temperature-Controlled Custom Bio-Pharmaceutical Finishing Services
9. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
10. Updated NIH Guidelines Offer Valuable Information on Asthma Diagnosis and Management
11. Six UK Hospitals Join Together in Using Varian Medical Oncology Information Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016  CytRx Corporation ... development company specializing in oncology, today announced that ... security agreement with Hercules Technology Growth Capital, Inc. ... $40 million in financing. --> ... first $25 million of financing under the loan ...
(Date:2/8/2016)... Maryland (PRWEB) , ... February 08, 2016 , ... Information ... BSI Web product. The upgrade represents a completely new technical foundation and is ... will offer a responsive design interface, significantly increased speed for search results, a streamlined ...
(Date:2/8/2016)... that its new website has gone live. On Thursday, Feb. 4, the company unveiled a re-envisioned ... Visit the new site: www.diplomat.is ... ... Diplomat Specialty Pharmacy ... "The goal was to reimagine the website and create a smarter, more comprehensive digital platform," said ...
(Date:2/5/2016)... Feb. 5, 2016  In the pharmaceutical industry the ... host of launch activities including the identification and engagement ... activity is especially high in the oncology therapeutic area ... Practices and the Role of Medical Affairs in Oncology ... on oncology therapies find better ways to utilize medical ...
Breaking Biology Technology:
(Date:2/3/2016)... --> --> Fourth quarter 2015:   ... compared with fourth quarter of 2014. Gross margin was 46% ... Earnings per share increased to SEK 6.39 (loss: 0.49). ... , --> --> January ... (233.6), up 1,142% compared with 2014. Gross margin was 43% ...
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
(Date:2/1/2016)... -- Rising sales of consumer electronics coupled ... gesture control market size through ... electronics coupled with new technological advancements to drive global ... through 2020   --> Rising ... to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):